NightHawk Biosciences (NYSE:NHWK) Stock Passes Below 200-Day Moving Average of $0.99

NightHawk Biosciences, Inc. (NYSE:NHWKGet Rating) shares crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $0.99 and traded as low as $0.77. NightHawk Biosciences shares last traded at $0.78, with a volume of 113,286 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Maxim Group downgraded NightHawk Biosciences from a “buy” rating to a “hold” rating in a report on Monday, April 3rd.

NightHawk Biosciences Stock Down 1.6 %

The firm has a market capitalization of $20.25 million, a P/E ratio of -0.42 and a beta of 0.50. The company’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $0.99. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.09.

NightHawk Biosciences (NYSE:NHWKGet Rating) last announced its earnings results on Friday, March 31st. The biopharmaceutical company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04). The business had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.60 million. NightHawk Biosciences had a negative net margin of 693.37% and a negative return on equity of 61.62%. Research analysts expect that NightHawk Biosciences, Inc. will post -1.31 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in NHWK. Bank of New York Mellon Corp purchased a new stake in NightHawk Biosciences in the third quarter worth approximately $25,000. Edmond DE Rothschild Holding S.A. purchased a new stake in NightHawk Biosciences during the third quarter valued at $25,000. Renaissance Technologies LLC bought a new position in NightHawk Biosciences in the third quarter valued at about $35,000. Virtu Financial LLC purchased a new position in NightHawk Biosciences in the fourth quarter worth about $53,000. Finally, Millennium Management LLC purchased a new stake in shares of NightHawk Biosciences during the 4th quarter valued at about $54,000. Institutional investors own 9.52% of the company’s stock.

About NightHawk Biosciences

(Get Rating)

NightHawk Biosciences, Inc, an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product.

Featured Stories

Receive News & Ratings for NightHawk Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NightHawk Biosciences and related companies with's FREE daily email newsletter.